GSK Valuation

Is G1SK34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of G1SK34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: G1SK34 (R$41.08) is trading below our estimate of fair value (R$108.48)

Significantly Below Fair Value: G1SK34 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for G1SK34?

Other financial metrics that can be useful for relative valuation.

G1SK34 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA7.3x
PEG Ratio1x

Price to Earnings Ratio vs Peers

How does G1SK34's PE Ratio compare to its peers?

The above table shows the PE ratio for G1SK34 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.7x
HYPE3 Hypera
7.7x12.0%R$13.1b
OFSA3 Ouro Fino Saúde Animal Participações
13xn/aR$1.2b
ZTS Zoetis
32.9x9.9%US$78.5b
MRK Merck KGaA
25.1x10.6%€65.9b
22.1x22.4%R$55.6b

Price-To-Earnings vs Peers: G1SK34 is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the peer average (19.7x).


Price to Earnings Ratio vs Industry

How does G1SK34's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: G1SK34 is good value based on its Price-To-Earnings Ratio (22.1x) compared to the Global Pharmaceuticals industry average (23.7x).


Price to Earnings Ratio vs Fair Ratio

What is G1SK34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

G1SK34 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.1x
Fair PE Ratio23.1x

Price-To-Earnings vs Fair Ratio: G1SK34 is good value based on its Price-To-Earnings Ratio (22.1x) compared to the estimated Fair Price-To-Earnings Ratio (23.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies